Detalles de la búsqueda
1.
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC.
Int J Cancer
; 153(3): 623-634, 2023 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37141294
2.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med
; 378(24): 2288-2301, 2018 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29863955
3.
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Lancet Oncol
; 14(8): 760-8, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23742877
4.
Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion.
Clin Genitourin Cancer
; 22(2): 467-475, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38228413
5.
Real-world KINDLE-Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non-small-cell lung cancer.
Cancer Med
; 12(2): 1247-1259, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35789068
6.
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
JTO Clin Res Rep
; 4(11): 100572, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37954964
7.
Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America.
Mol Clin Oncol
; 16(1): 6, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34881026
8.
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
J Thorac Oncol
; 17(2): 309-323, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34626838
9.
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
J Thorac Oncol
; 16(4): 653-664, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33333328
10.
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
J Thorac Oncol
; 16(11): 1909-1924, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34311108
11.
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
J Clin Oncol
; 39(6): 619-630, 2021 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33439693
12.
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
J Clin Oncol
; 39(21): 2327-2338, 2021 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33513313
13.
Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
JCO Glob Oncol
; 7: 550-558, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33856896
14.
Consensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries.
JCO Glob Oncol
; 7: 538-544, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33856897
15.
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
J Clin Oncol
; 38(22): 2530-2542, 2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32459597
16.
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
J Clin Oncol
; 38(21): 2369-2379, 2020 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32468956
17.
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Lancet Respir Med
; 7(5): 387-401, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30922878
18.
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet Respir Med
; 7(7): 569-580, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31103412
19.
Breast cancer in Latin America: results of the Latin American and Caribbean Society of Medical Oncology/Breast Cancer Research Foundation expert survey.
Cancer
; 113(8 Suppl): 2359-65, 2008 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18837031
20.
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Lancet Oncol
; 14: 760-768, julio, 2013. tab
Artículo
en Inglés
| URUCAN | ID: bcc-4676